Skip to main content
OpenTrials
Completed

NCT Number: NCT02404207

Soybean Oil Trial of cArdiovascular Risk

The study will determine the effects of different types of soybean oils on biomarkers of risk for cardiovascular disease and diabetes. There will be four 4-week diet periods in which participants will consume the following oils, within the context of a controlled diet: soybean oil, high-oleic soybean oil, blend of high oleic soybean oil & fully hydrogenated soybean oil, and blend of palm olein & palm stearin.

Completed

Looking for future studies?

Notify Me

Key information

Age range

30 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

USDA-ARS, Beltsville Human Nutrition Research Center

Beltsville, Maryland, 20705, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 30 to 70 years at beginning of study
  • LDL-cholesterol between 120 and 160 mg/dl
  • Less than 2+ risk factors for coronary heart disease (risk factors include: blood pressure > 140/90 mm Hg or on blood pressure medication; HDL-cholesterol < 40 mg/dl; age greater than 45 yrs for males & greater than 55 yrs for females; family history of premature coronary heart disease (CHD in male first degree relative <55 years; CHD in female first degree relative <65 years)

Exclusion criteria

  • Presence of kidney disease, liver disease, gout, hyperthyroidism, untreated or unstable hypothyroidism, certain cancers, gastrointestinal disease, pancreatic disease, other metabolic diseases, or malabsorption syndromes
  • Use of prescription or over-the-counter medications or supplements that alter lipid metabolism.
  • Women who have given birth during the previous 12 months
  • Pregnant women or women who plan to become pregnant or become pregnant during the study
  • Lactating women
  • Type 2 diabetes requiring the use of oral antidiabetic agents or insulin
  • History of bariatric or certain other surgeries related to weight control
  • Use of prescription or over-the-counter antiobesity medications or supplements (e.g., phenylpropanolamine, ephedrine, caffeine) during and for at least 6 months prior to the start of the study or a history of a surgical intervention for obesity
  • Unwillingness to abstain from herbal supplements for two weeks prior to the study and during the study
  • Smokers or other tobacco users (during 6 months prior to the start of the study)
  • History of eating disorders or other dietary patterns which are not consistent with the dietary intervention (e.g., vegetarians, very low fat diets, high protein diets)
  • Known (self-reported) allergy or adverse reaction to study foods
  • Active cardiovascular disease (such as a heart attack or procedure within the past three months or participation in a cardiac rehabilitation program within the last three months, stroke, or history/treatment for transient ischemic attacks in the past three months, or documented history of pulmonary embolus in the past six months)
  • Unable or unwilling to give informed consent or communicate with study staff
  • Self-report of alcohol or substance abuse within the past 12 months and/or current acute treatment or rehabilitation program for these problems (long-term participation in Alcoholics Anonymous is not an exclusion)
  • Other medical, psychiatric, or behavioral factors that in the judgment of the Principal Investigator may interfere with study participation or the ability to follow the intervention protocol

Treatment and study plan

soybean oil

Other

Participants will be fed soybean oil as part of a controlled (typical American) diet.

High-oleic soybean oil

Other

Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.

High-oleic soybean oil + fully hydrogenated soybean oil

Other

Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.

Palm olein + palm stearin

Other

Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.

Primary outcomes

  1. Change in lipid profile

    Time frame: At baseline and end of each 4-week diet period

    Lipids and lipoproteins, such as total cholesterol, LDL-cholesterol, HDL-cholesterol, triacylglycerides, Apo AI, ApoAII, ApoB, apolipoprotein size, and cholesterol ester composition, will be measured in the blood.

Secondary outcomes

  1. Change in systemic inflammation

    Time frame: At baseline and end of each 4-week diet period

    Markers of systemic inflammation will be measured, such as IL-6, CRP, and isoprostanes.

  2. Change in hemostasis

    Time frame: At baseline and end of each 4-week diet period

    Markers of hemostasis will be measured, such as fibrinogen and factor VIIc.

  3. Change in oxidation

    Time frame: At baseline and end of each 4-week diet period

    Markers of oxidation will be measured, such as 4-hydroxynonenal, vitamin E, oxidized LDL, lipid hydroperoxides, and malondialdehyde.

  4. Change in vascular health

    Time frame: At baseline and end of each 4-week diet period

    Markers of vascular health will be measured, such as ICAM, VCAM, eSelectin, and blood pressure.

  5. Change in glucose

    Time frame: At baseline and end of each 4-week diet period

    Fasting blood glucose will be measured.

  6. Change in insulin

    Time frame: At baseline and end of each 4-week diet period

    Fasting insulin will be measured.

  7. Change in body composition

    Time frame: At baseline and end of each 4-week diet period

    Dual-energy x-ray absorptiometry (DEXA; fat and lean mass, visceral fat) will be measured.

  8. Change in waist circumference

    Time frame: At baseline and end of each 4-week diet period

Sponsors and collaborators

Lead sponsor

USDA Beltsville Human Nutrition Research Center

Fed

Registry information

Official study title

The Effect of High-Oleic Soybean Oil on Biomarkers of Risk for Metabolic Syndrome

Acronym: STAR

Important dates

Study start
2015
Primary completion
2015
Study completion
2015
First posted
Mar 31, 2015
Registry last updated
May 12, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.